Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement
© 2021 The Authors. Journal of Medical Virology Published by Wiley Periodicals LLC..
This study describes the baseline characteristics and treatment patterns of US patients hospitalized with a diagnosis of coronavirus disease 2019 (COVID-19) and pulmonary involvement. Patients hospitalized with pulmonary involvement due to COVID-19 (first hospitalization) were identified in the IBM Explorys® electronic health records database. Demographics, baseline clinical characteristics, and in-hospital medications were assessed. For evaluation of in-hospital medications, results were stratified by race, geographic region, age, and month of admission. Of 6564 hospitalized patients with COVID-19-related pulmonary involvement, 50.4% were male, and mean (SD) age was 62.6 (16.4) years; 75.2% and 23.6% of patients were from the South and Midwest, respectively, and 50.2% of patients were African American. Compared with African American patients, a numerically higher proportion of White patients received dexamethasone (19.7% vs. 31.8%, respectively), nonsteroidal anti-inflammatory drugs (NSAIDs; 27.1% vs. 34.9%), bronchodilators (19.8% vs. 29.5%), and remdesivir (9.3% vs. 21.0%). Numerically higher proportions of White patients than African American patients received select medications in the South but not in the Midwest. Compared with patients in the South, a numerically higher proportion of patients in the Midwest received dexamethasone (20.1% vs. 34.5%, respectively), NSAIDs (19.6% vs. 55.7%), bronchodilators (15.9% vs. 41.3%), and remdesivir (10.6% vs. 23.1%). Inpatient use of hydroxychloroquine decreased over time, whereas the use of dexamethasone and remdesivir increased over time. Among US patients predominantly from the South and Midwest hospitalized with COVID-19 and pulmonary involvement, differences were seen in medication use between different races, geographic regions, and months of hospitalization.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
---|---|
Enthalten in: |
Journal of medical virology - 93(2021), 9 vom: 15. Sept., Seite 5367-5375 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Best, Jennie H [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 30.07.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/jmv.27049 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM324668090 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM324668090 | ||
003 | DE-627 | ||
005 | 20231225190816.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/jmv.27049 |2 doi | |
028 | 5 | 2 | |a pubmed24n1082.xml |
035 | |a (DE-627)NLM324668090 | ||
035 | |a (NLM)33913536 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Best, Jennie H |e verfasserin |4 aut | |
245 | 1 | 0 | |a Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 30.07.2021 | ||
500 | |a Date Revised 07.12.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021 The Authors. Journal of Medical Virology Published by Wiley Periodicals LLC. | ||
520 | |a This study describes the baseline characteristics and treatment patterns of US patients hospitalized with a diagnosis of coronavirus disease 2019 (COVID-19) and pulmonary involvement. Patients hospitalized with pulmonary involvement due to COVID-19 (first hospitalization) were identified in the IBM Explorys® electronic health records database. Demographics, baseline clinical characteristics, and in-hospital medications were assessed. For evaluation of in-hospital medications, results were stratified by race, geographic region, age, and month of admission. Of 6564 hospitalized patients with COVID-19-related pulmonary involvement, 50.4% were male, and mean (SD) age was 62.6 (16.4) years; 75.2% and 23.6% of patients were from the South and Midwest, respectively, and 50.2% of patients were African American. Compared with African American patients, a numerically higher proportion of White patients received dexamethasone (19.7% vs. 31.8%, respectively), nonsteroidal anti-inflammatory drugs (NSAIDs; 27.1% vs. 34.9%), bronchodilators (19.8% vs. 29.5%), and remdesivir (9.3% vs. 21.0%). Numerically higher proportions of White patients than African American patients received select medications in the South but not in the Midwest. Compared with patients in the South, a numerically higher proportion of patients in the Midwest received dexamethasone (20.1% vs. 34.5%, respectively), NSAIDs (19.6% vs. 55.7%), bronchodilators (15.9% vs. 41.3%), and remdesivir (10.6% vs. 23.1%). Inpatient use of hydroxychloroquine decreased over time, whereas the use of dexamethasone and remdesivir increased over time. Among US patients predominantly from the South and Midwest hospitalized with COVID-19 and pulmonary involvement, differences were seen in medication use between different races, geographic regions, and months of hospitalization | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Observational Study | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a SARS coronavirus | |
650 | 4 | |a antiviral agents | |
650 | 4 | |a cytokine/chemokine | |
650 | 4 | |a disease control | |
650 | 4 | |a immune responses | |
650 | 4 | |a immunodulators | |
650 | 4 | |a inflammation | |
650 | 4 | |a respiratory tract | |
650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Bronchodilator Agents |2 NLM | |
650 | 7 | |a remdesivir |2 NLM | |
650 | 7 | |a 3QKI37EEHE |2 NLM | |
650 | 7 | |a Adenosine Monophosphate |2 NLM | |
650 | 7 | |a 415SHH325A |2 NLM | |
650 | 7 | |a Hydroxychloroquine |2 NLM | |
650 | 7 | |a 4QWG6N8QKH |2 NLM | |
650 | 7 | |a Dexamethasone |2 NLM | |
650 | 7 | |a 7S5I7G3JQL |2 NLM | |
650 | 7 | |a Alanine |2 NLM | |
650 | 7 | |a OF5P57N2ZX |2 NLM | |
700 | 1 | |a Kong, Amanda M |e verfasserin |4 aut | |
700 | 1 | |a Kaplan-Lewis, Emma |e verfasserin |4 aut | |
700 | 1 | |a Brawley, Otis W |e verfasserin |4 aut | |
700 | 1 | |a Baden, Rachel |e verfasserin |4 aut | |
700 | 1 | |a Zazzali, James L |e verfasserin |4 aut | |
700 | 1 | |a Miller, Karen S |e verfasserin |4 aut | |
700 | 1 | |a Loveless, James |e verfasserin |4 aut | |
700 | 1 | |a Jariwala-Parikh, Krutika |e verfasserin |4 aut | |
700 | 1 | |a Mohan, Shalini V |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 93(2021), 9 vom: 15. Sept., Seite 5367-5375 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
773 | 1 | 8 | |g volume:93 |g year:2021 |g number:9 |g day:15 |g month:09 |g pages:5367-5375 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.27049 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 93 |j 2021 |e 9 |b 15 |c 09 |h 5367-5375 |